19/75 patients (25.3%) showed p16INK4a-overexpression, defined as diffuse staining in more than 50% of tumor cells; 56/75 patients (74.67%) were tested p16INK4a-negative, showing only focal or no staining at all. The gene discussed is CDKN2A; the disease is neoplasm.